CRISPR Partner Vertex Records $54.3M Casgevy Q4 Sales, $115.8M in 2025
Vertex Pharmaceuticals recorded $54.3 million in Casgevy sales during Q4 and $115.8 million for full-year 2025 under its partnership with CRISPR Therapeutics. The growing gene therapy uptake contributes to potential royalty upside for CRSP as Vertex’s overall Q4 revenue climbed 10% to $3.19 billion.
1. Q4 and 2025 Casgevy Sales
Vertex recorded $54.3 million in Casgevy sales in the fourth quarter and $115.8 million for full-year 2025, up sharply from $16.9 million in the prior quarter and surpassing its $100 million annual revenue target. Casgevy’s performance highlights accelerating market adoption of the one-shot gene therapy.
2. Partnership and Royalty Structure
Under the 2021 collaboration, Vertex leads global development and commercialization of Casgevy, while CRISPR Therapeutics receives royalties on net sales. As sales scale, royalty payments are expected to become a meaningful contributor to CRSP’s revenue base.
3. Growth Drivers and Outlook
Vertex plans pediatric label expansion for Casgevy in patients aged five to 11 and anticipates additional approvals in new indications, underpinning further sales growth. The company’s 2026 guidance forecasts over $500 million in non-CF therapy revenues, reflecting higher Casgevy infusion volumes and launch momentum.